Solving the Pharma Talent Puzzle in China
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
CR Pharmaceutical Group Limited was set up in response to the requirement of the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) to “create a state-owned pharmaceutical platform” in 2007. It is an integrated enterprise group combining pharmaceutical R&D, manufacturing and production, as well as marketing under one umbrella. Leveraging its strong industrial base leading competitive advantages, CR Pharma is striving to “become the leader in China’s pharmaceutical industry”. In 2013, both turnover and assets of the company exceeded HK$100 billion, and CR Pharma ranked second in terms of overall strength in China’s pharmaceutical industry. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange.
CR Pharma owns two grade-1 profit centers, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., as well as famous companies including Shandong Dong-E-E-Jiao Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., China Anhui World-Best Pharmaceutical Co., Ltd., and China Resources Pien Tze Huang Pharmaceutical Co., Ltd. Among them, CR Sanjiu (000999), CR Double-Crane, and Dong-E-E-Jiao (000423) are A-share pharmaceutical companies listed in China.
In the area of pharmaceutical manufacturing, CR Pharma is involved in natural medicine, Chinese medicine, chemical drugs, biological drugs and nutritional supplements. It ranked number one in the 2011 China Top 100 Pharmaceutical Manufacturing Enterprises, and owns well-known brands including “999”, “Double-Crane”, “Saike”, “Dong-E”, “Zizhu”, and “Yu Ting”.
In terms of retail and distribution, its business covers wholesale distribution of drugs, medical equipment, healthcare products, logistics, distribution, retail and supply chain value-added services. It ranks second among China’s pharmaceutical businesses and is the market leader in the areas of hospital drugs distribution and extended services, and modern logistics and distribution services in China.
CR Pharma possesses abundant and quality R&D resources, and strong independent innovation capabilities. It has established two national research centres for Chinese patent medicine and traditional Chinese gelatine medicine (Ejiao series), and numerous provincial level technology centres, serving as the R&D base for birth control and genital health drugs. It is leading the industry in pharmaceutical preparation and new pharmaceutical controlled-release technologies within China and is world-leading in its core R&D technology in pharmaceutical nucleoside intermediates. Through innovation and collaboration, CR Pharma will continue to focus on providing high-quality and reliable products and services to the public and will strive to become the market leader in China’s pharmaceutical industry.
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities.…
2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how…
Shawn Leung, CEO of Chinese biotech SinoMab, discusses the”Biotech 3.0″ philosophy that characterizes the company as it strives for both scientific innovation and differentiation. He highlights SinoMab’s atopic dermatitis and…
Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert…
Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR,…
Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading…
Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses…
EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster,…
Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today…
See our Cookie Privacy Policy Here
